Samidorphan

Identification

Summary

Samidorphan is a novel opioid-system modulator, similar to naltrexone, that functions primarily as a μ-opioid receptor antagonist in vivo and is used primarily in combination with antipsychotics to reduce their metabolic dysfunction-associated adverse effects.

Brand Names

Lybalvi

Generic Name

Samidorphan

DrugBank Accession Number

DB12543

Background

Olanzapine is an effective atypical antipsychotic that, like other antipsychotics, is associated with weight gain, metabolic dysfunction, and increased risk of type II diabetes.^5,6 Samidorphan is a novel opioid antagonist structurally related to naltrexone, with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability, and a longer half-life, making it an attractive candidate for oral dosing.^1,5,11 Although antipsychotic-induced weight gain is incompletely understood, it is thought that the opioid system plays a key role in feeding and metabolism, such that opioid antagonism may be expected to ameliorate these negative effects. Samidorphan has been shown in animal models and clinical trials to ameliorate olanzapine-induced weight gain and metabolic dysfunction.^5,6

Samidorphan was first approved as a variety of fixed-dose combination tablets with olanzapine by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™ by Alkermes Inc.¹¹

Type

Small Molecule

Groups

Approved, Investigational

Structure

Similar Structures

Weight: Average: 370.449
Monoisotopic: 370.189257325
Chemical Formula: C₂₁H₂₆N₂O₄

Synonyms

Samidorphan

External IDs

ALKS 33
ALKS-33
RDC-0313
RDC-0313-00

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Samidorphan is indicated in combination with olanzapine for the treatment of bipolar I disorder, either as an adjunct to lithium or valproate or as monotherapy for the acute treatment of manic or mixed episodes or as maintenance therapy, and for the treatment of schizophrenia in adults.¹¹

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Dose Form
Used in combination to manage	Bipolar 1 disorder	Combination Product in combination with: Olanzapine (DB00334)	••••••••••••	•••••	••••••
Used as adjunct in combination to treat	Bipolar disorder with manic or mixed episodes	Combination Product in combination with: Olanzapine (DB00334)	••••••••••••	•••••	••••••
Used in combination to treat	Bipolar disorder with manic or mixed episodes	Combination Product in combination with: Olanzapine (DB00334)	••••••••••••	•••••	••••••
Used as adjunct in combination to treat	Bipolar disorder with manic or mixed episodes	Combination Product in combination with: Olanzapine (DB00334)	••••••••••••	•••••	••••••
Used in combination to treat	Schizophrenia	Combination Product in combination with: Olanzapine (DB00334)	••••••••••••	•••••	••••••

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Samidorphan, a novel opioid-system modulator, functions primarily as a μ-opioid receptor antagonist and as a κ/δ-opioid receptor partial agonist in vitro with an overall profile consistent with a μ-opioid receptor antagonist in vivo and is currently used to counteract olanzapine-induced adverse effects of weight gain and metabolic dysfunction.¹¹ Samidorphin generally has a mild side effect profile. As an opioid antagonist, it can potentiate opioid withdrawal in dependent patients; it should not be administered within seven days from the last use of short-acting opioids and at least 14 days after cessation of long-acting opioids. Similarly, samidorphan use may lead to life-threatening opioid overdose, either in patients who attempt to overcome the samidorphan-induced opioid blockade or resume opioid use when therapy is interrupted or discontinued.¹¹

Several other effects may be noted in combination with olanzapine, including increased risk for potentially fatal cerebrovascular events in elderly patients with dementia-related psychosis, neuroleptic malignant syndrome, hyperprolactinemia, and tardive dyskinesia. Olanzapine is associated with an increased risk of metabolic dysfunction, including hyperglycemia, type II diabetes, dyslipidemia, and weight gain. Patients may be at increased risk for orthostatic hypotension and syncope, particularly in patients with known cardiovascular/cerebrovascular disease. Leukopenia, neutropenia, and agranulocytosis may occur and should be monitored for; patients with a history of seizure should also be monitored. This combination may exhibit anticholinergic (antimuscarinic) effects. It should be used with caution with other anticholinergic drugs and in patients with urinary retention, prostatic hypertrophy, constipation, paralytic ileus, or related conditions. Serious allergic reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have been reported. Patients may be at increased risk of cognitive and motor impairment; caution while operating machinery is recommended.¹¹

Mechanism of action

Samidorphan is a novel naltrexone analogue containing a 3-carboxamido group that functions as an opioid receptor modulator, both in vitro and in vivo.^1,11 Numerous in vitro studies have demonstrated that samidorphan binds with high affinity to the μ-, κ-, and δ-opioid receptors with K_i values of 0.052 ± 0.0044, 0.23 ± 0.018, and 2.7 ± 0.36 nM, respectively.^2,3,4,11 Samidorphan acts as an antagonist at the μ-opioid receptor when it signals through G_αi proteins, a partial agonist when the receptor signals through G_αoA, G_αoB, and G_αz proteins, and essentially lacks β-arrestin-mediated signalling; samidorphan also acts as a partial agonist at both the κ- and δ-opioid receptors in vitro.² In addition, both the major N-dealkylated and the major N-oxide human metabolites bind to the μ-, κ-, and δ-opioid receptors (K_i values of 0.26, 23, and 56, and 8, 110, and 280 nM, respectively); the former functions as a μ-opioid receptor agonist and the latter as an antagonist.¹¹ Overall, samidorphan functions primarily as a μ-opioid antagonist in vivo.¹

Olanzapine is an efficacious antipsychotic whose use is limited, in part, by known adverse effects mediated through metabolic dysfunction: hyperglycemia/diabetes mellitus, hyperlipidemia, and weight gain.^1,5 The exact mechanisms behind this metabolic dysfunction are incompletely understood, but it is known that opioid signalling is involved in feeding and metabolism.⁵ Clinical studies have demonstrated that the addition of samidorphan to olanzapine helps mitigate its metabolic-related adverse effects; presumably, this is due to opioid receptor signalling, though the exact mechanism remains to be determined.^1,6,5 The appropriateness of samidorphan in combination therapy is due in part to its relatively mild side effect profile and low abuse potential.^6,7

Target	Actions	Organism
AMu-type opioid receptor	antagonist	Humans
UKappa-type opioid receptor	partial agonist	Humans
UDelta-type opioid receptor	partial agonist	Humans

Absorption

Samidorphan pharmacokinetics are linear over the range of clinically relevant concentrations, and steady-state kinetics are reached by seven days with once-daily oral administration. Upon reaching steady-state, with a once-daily dose of 10 mg samidorphan combined with 20 mg olanzapine, samidorphan has a mean C_max of 45.1 ± 11.4 ng/mL and an AUC_24h of 364 ± 112 ng*h/mL. Samidorphan has an absolute oral bioavailability of 69% and a T_max of 1-2 hours.^8,9,11

Samidorphan pharmacokinetics are not significantly impacted by food; following a high-fat meal, the C_max was 0.85 (90% CI 0.76, 0.94) and the AUC 1.03 (90% CI 1.0, 1.05) that for the fasted state.^9,10,11

Volume of distribution

Samidorphan following a single 10 mg oral dose had an apparent volume of distribution between 336.59 ± 75.42 and 557.6 ± 120.51 L, depending on age, gender, and concomitant food consumption.⁹

Protein binding

Samidorphan is between 23 and 33 percent bound to plasma proteins.¹¹

Metabolism

Samidorphan is primarily metabolized by CYP3A4, with minor contributions from CYP3A5, CYP2C19, and CYP2C8.¹¹ The main metabolism products are RDC-9986 (an N-dealkylated metabolite) and RDC-1066 (an N-oxide metabolite); although both metabolites have a nanomolar affinity for the μ-, κ-, and δ-opioid receptors, neither is thought to contribute to the pharmacological effects of samidorphan.^11,12

Route of elimination

Samidorphan is primarily renally excreted, with 67% of unchanged parent and metabolites eliminated in urine and another 16% in feces.¹¹

Half-life

Samidorphan has a mean half-life of 7-11 hours.^8,9,10,11

Clearance

Samidorphan has a mean clearance of 35-45 L/h.^9,11

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

There is limited information regarding samidorphan overdose. During clinical trials for the combination of olanzapine and samidorphan, overdose was recognized in 7/861 patients, none of which were fatal. One patient who ingested 5.5- and 11-times the maximum daily dosage of olanzapine and samidorphan, respectively, was unresponsive and admitted to the hospital but stabilized within two days. As there are no known antidotes for overdose with this combination, symptomatic and supportive measures are recommended.¹¹

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
1,2-Benzodiazepine	The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Samidorphan.
Abametapir	The serum concentration of Samidorphan can be increased when it is combined with Abametapir.
Acetazolamide	The risk or severity of CNS depression can be increased when Acetazolamide is combined with Samidorphan.
Acetophenazine	The risk or severity of CNS depression can be increased when Acetophenazine is combined with Samidorphan.
Agomelatine	The risk or severity of CNS depression can be increased when Agomelatine is combined with Samidorphan.

Food Interactions

Take with or without food. Food has only a minor effect on samidorphan pharmacokinetics.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Samidorphan L-malate	0AJQ5N56E0	1204592-75-5	RARHXUAUPNYAJF-QSYGGRRVSA-N

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Lybalvi	Samidorphan L-malate (10 mg/1) + Olanzapine (15 mg/1)	Tablet, film coated	Oral	Alkermes, Inc.	2021-09-20	Not applicable
Lybalvi	Samidorphan L-malate (10 mg/1) + Olanzapine (10 mg/1)	Tablet, film coated	Oral	Alkermes, Inc.	2021-09-20	Not applicable
Lybalvi	Samidorphan L-malate (10 mg/1) + Olanzapine (20 mg/1)	Tablet, film coated	Oral	Alkermes, Inc.	2021-09-20	Not applicable
Lybalvi	Samidorphan L-malate (10 mg/1) + Olanzapine (5 mg/1)	Tablet, film coated	Oral	Alkermes, Inc.	2021-09-20	Not applicable

Chemical Identifiers

UNII: 7W2581Z5L8
CAS number: 852626-89-2
InChI Key: RYIDHLJADOKWFM-MAODMQOUSA-N
InChI: InChI=1S/C21H26N2O4/c22-19(26)15-4-3-13-9-16-21(27)6-5-14(24)10-20(21,17(13)18(15)25)7-8-23(16)11-12-1-2-12/h3-4,12,16,25,27H,1-2,5-11H2,(H2,22,26)/t16-,20-,21-/m1/s1
IUPAC Name: (1R,9R,10S)-17-(cyclopropylmethyl)-3,10-dihydroxy-13-oxo-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2,4,6-triene-4-carboxamide
SMILES: NC(=O)C1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]4(CC(=O)CC[C@@]34O)C2=C1O

References

Synthesis Reference

Wentland MP, Lu Q, Lou R, Bu Y, Knapp BI, Bidlack JM: Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone. Bioorg Med Chem Lett. 2005 Apr 15;15(8):2107-10. doi: 10.1016/j.bmcl.2005.02.032.

General References

Chaudhary AMD, Khan MF, Dhillon SS, Naveed S: A Review of Samidorphan: A Novel Opioid Antagonist. Cureus. 2019 Jul 15;11(7):e5139. doi: 10.7759/cureus.5139. [Article]
Bidlack JM, Knapp BI, Deaver DR, Plotnikava M, Arnelle D, Wonsey AM, Fern Toh M, Pin SS, Namchuk MN: In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder. J Pharmacol Exp Ther. 2018 Nov;367(2):267-281. doi: 10.1124/jpet.118.249839. Epub 2018 Aug 14. [Article]
Wentland MP, Lu Q, Lou R, Bu Y, Knapp BI, Bidlack JM: Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone. Bioorg Med Chem Lett. 2005 Apr 15;15(8):2107-10. doi: 10.1016/j.bmcl.2005.02.032. [Article]
Wentland MP, Lou R, Lu Q, Bu Y, Denhardt C, Jin J, Ganorkar R, VanAlstine MA, Guo C, Cohen DJ, Bidlack JM: Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94. doi: 10.1016/j.bmcl.2009.02.078. Epub 2009 Feb 25. [Article]
Cunningham JI, Eyerman DJ, Todtenkopf MS, Dean RL, Deaver DR, Sanchez C, Namchuk M: Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates. J Psychopharmacol. 2019 Oct;33(10):1303-1316. doi: 10.1177/0269881119856850. Epub 2019 Jul 11. [Article]
Martin WF, Correll CU, Weiden PJ, Jiang Y, Pathak S, DiPetrillo L, Silverman BL, Ehrich EW: Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia. Am J Psychiatry. 2019 Jun 1;176(6):457-467. doi: 10.1176/appi.ajp.2018.18030280. Epub 2019 Mar 8. [Article]
Pathak S, Vince B, Kelsh D, Setnik B, Nangia N, DiPetrillo L, Puhl MD, Sun L, Stanford AD, Ehrich E: Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study. J Clin Pharmacol. 2019 Feb;59(2):218-228. doi: 10.1002/jcph.1343. Epub 2018 Nov 26. [Article]
Sun L, McDonnell D, von Moltke L: Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia. Clin Ther. 2018 Nov;40(11):1845-1854.e2. doi: 10.1016/j.clinthera.2018.09.002. Epub 2018 Oct 20. [Article]
Kumar V, Lu H, Hard M, von Moltke L: Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age. Drugs R D. 2019 Sep;19(3):277-287. doi: 10.1007/s40268-019-00280-5. [Article]
Sun L, McDonnell D, Liu J, von Moltke L: Effect of Food on the Pharmacokinetics of a Combination of Olanzapine and Samidorphan. Clin Pharmacol Drug Dev. 2019 May;8(4):503-510. doi: 10.1002/cpdd.688. Epub 2019 Mar 28. [Article]
FDA Approved Drug Products: LYBALVI (olanzapine and samidorphan) tablets [Link]
DEA Proposal: Removal of Samidorphan from Controlled Substance Schedule [Link]
DEA: Removal of Samidorphan from Schedule II [Link]

External Links

PubChem Compound: 11667832
PubChem Substance: 347828769
ChemSpider: 23259667
BindingDB: 50165049
RxNav: 2559612
ChEMBL: CHEMBL426084
ZINC: ZINC000028478244
Wikipedia: Samidorphan

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
3	Recruiting	Treatment	Bipolar 1 Disorder / Schizophrenia	1
2	Completed	Treatment	Alcohol Dependency	1
2	Completed	Treatment	Alcohol Use Disorders (AUD) / Schizophrenia	1
2	Completed	Treatment	Binge Eating Disorder (BED)	1
2	Completed	Treatment	Schizophrenia	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Tablet, film coated	Oral

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US8778960	No	2014-07-15	2032-02-13
US9126977	No	2015-09-08	2031-08-23
US9517235	No	2016-12-13	2031-08-23
US10716785	No	2020-07-21	2031-08-23
US10300054	No	2019-05-28	2031-08-23
US9119848	No	2015-09-01	2031-08-30
US7956187	No	2011-06-07	2021-10-31
US8252929	No	2012-08-28	2021-10-31
US7262298	No	2007-08-28	2025-11-23
US11185541	No	2021-11-30	2031-08-23
US11241425	No	2011-08-23	2031-08-23
US11351166	No	2011-08-23	2031-08-23
US11707466	No	2021-11-12	2041-11-12
US11793805	No	2011-08-23	2031-08-23

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	196.6-196.8	DEA
water solubility	freely soluble	DEA
pKa	8.3, 10.1	FDA Label

Predicted Properties

Property	Value	Source
Water Solubility	0.629 mg/mL	ALOGPS
logP	1.09	ALOGPS
logP	0.29	Chemaxon
logS	-2.8	ALOGPS
pKa (Strongest Acidic)	7.92	Chemaxon
pKa (Strongest Basic)	9.46	Chemaxon
Physiological Charge	1	Chemaxon
Hydrogen Acceptor Count	5	Chemaxon
Hydrogen Donor Count	3	Chemaxon
Polar Surface Area	103.86 Å²	Chemaxon
Rotatable Bond Count	3	Chemaxon
Refractivity	101.04 m³·mol^-1	Chemaxon
Polarizability	39.39 Å³	Chemaxon
Number of Rings	5	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-014i-0009000000-6bdc701626646b9d958f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0uk9-0009000000-48bf7e94ae8bfedf3742
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0udr-0009000000-fbc3333cd2450f8aae0a
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-00or-1009000000-1500b2dd2eb97cc0c092
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0ab9-1429000000-4e5554594a235516f5eb
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-00ko-3049000000-fce3e5668c9ce64f4667
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å²)	Source type	Source
[M-H]-	193.02089	predicted	DeepCCS 1.0 (2019)
[M+H]+	195.41644	predicted	DeepCCS 1.0 (2019)
[M+Na]+	201.3622	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Mu-type opioid receptor

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Antagonist
Curator comments: Samidorphan binds the μ-opioid receptor with a Ki of 0.052 ± 0.0044 nM.

General Function: Voltage-gated calcium channel activity
Specific Function: Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name: OPRM1
Uniprot ID: P35372
Uniprot Name: Mu-type opioid receptor
Molecular Weight: 44778.855 Da

References

FDA Approved Drug Products: LYBALVI (olanzapine and samidorphan) tablets [Link]

Details2. Kappa-type opioid receptor

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Partial agonist
Curator comments: Samidorphan binds the κ-opioid receptor with a Ki of 0.23 ± 0.018 nM.

General Function: Opioid receptor activity
Specific Function: G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name: OPRK1
Uniprot ID: P41145
Uniprot Name: Kappa-type opioid receptor
Molecular Weight: 42644.665 Da

References

FDA Approved Drug Products: LYBALVI (olanzapine and samidorphan) tablets [Link]

Details3. Delta-type opioid receptor

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Partial agonist
Curator comments: Samidorphan binds the δ-opioid receptor with a Ki of 2.7 ± 0.36 nM.

General Function: Opioid receptor activity
Specific Function: G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name: OPRD1
Uniprot ID: P41143
Uniprot Name: Delta-type opioid receptor
Molecular Weight: 40368.235 Da

References

FDA Approved Drug Products: LYBALVI (olanzapine and samidorphan) tablets [Link]

Enzymes

Details1. Cytochrome P450 3A4

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

References

FDA Approved Drug Products: LYBALVI (olanzapine and samidorphan) tablets [Link]

Details2. Cytochrome P450 3A5

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Oxygen binding
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP3A5
Uniprot ID: P20815
Uniprot Name: Cytochrome P450 3A5
Molecular Weight: 57108.065 Da

References

FDA Approved Drug Products: LYBALVI (olanzapine and samidorphan) tablets [Link]

Details3. Cytochrome P450 2C19

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Steroid hydroxylase activity
Specific Function: Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name: CYP2C19
Uniprot ID: P33261
Uniprot Name: Cytochrome P450 2C19
Molecular Weight: 55930.545 Da

References

FDA Approved Drug Products: LYBALVI (olanzapine and samidorphan) tablets [Link]

Details4. Cytochrome P450 2C8

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Steroid hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP2C8
Uniprot ID: P10632
Uniprot Name: Cytochrome P450 2C8
Molecular Weight: 55824.275 Da

References

FDA Approved Drug Products: LYBALVI (olanzapine and samidorphan) tablets [Link]

Drug created at October 20, 2016 22:47 / Updated at June 09, 2021 08:40

Samidorphan

Identification

Structure for Samidorphan (DB12543)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Collision Cross Sections (CCS)

Targets

References

References

References

Enzymes

References

References

References

References